Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Dr. Mesa Discusses the Management of Patients With MPNs

April 14th 2018

Ruben Mesa, MD, director, The Mays Cancer Center, the newly named center of UT Health San Antonio MD Anderson Cancer Center, discusses the management of patients with myeloproliferative neoplasms.

ASCT Remains Significant Upfront Option in AL Amyloidosis

April 12th 2018

Investigators found that autologous stem-cell transplantation improved overall survival and reduced treatment-related mortality in patients with immunoglobulin light chain amyloidosis.

Dr. Mesa Discusses Emerging Treatments for MPNs

April 5th 2018

Ruben Mesa, MD, director, The Mays Cancer Center, the newly named center of UT Health San Antonio MD Anderson Cancer Center, discusses emerging treatment for myeloproliferative neoplasms (MPNs).

FDA Grants Moxetumomab Pasudotox Priority Review for Hairy Cell Leukemia

April 4th 2018

The FDA has granted a priority review to moxetumomab pasudotox for the treatment of adult patients with hairy cell leukemia who have received at least 2 prior lines of therapy.

MRD Prognostic of Poorer Outcomes in AML

April 2nd 2018

Molecular minimal residual disease was associated with a higher rate of relapse and a lower rate of relapse-free survival and overall survival for patients with newly-diagnosed acute myeloid leukemia.

Dr. Mauro Discusses Updates in CML

April 2nd 2018

Michael J. Mauro, MD, a hematologist and leader of the Myeloproliferative Neoplasms Program at Memorial Sloan Kettering Cancer Center, discusses updates in chronic myeloid leukemia.

Novel Radiolabeled ADC Could Improve Outcomes in High-Risk AML

April 2nd 2018

Older patients with active, relapsed, or refractory acute myeloid leukemia have a low survival rate, very poor risk assessments, and limited therapeutic options, with conventional care consisting primarily of salvage chemotherapy.

Nivolumab Delivers Durable Response in Hodgkin Lymphoma at 18 Months

April 2nd 2018

In an extended follow-up of results from the CheckMate-205 trial, nivolumab (Opdivo) induced an overall objective response rate of 69% in patients with relapsed/refractory classical Hodgkin lymphoma after autologous hematopoietic cell transplantation.

Dr. Goldberg on FDA-Approved Agents for Patients With AML

April 2nd 2018

Stuart L. Goldberg, MD, hematologist, John Theurer Cancer Center, discusses the use of 4 FDA-approved agents for patients with acute myeloid leukemia (AML) with varying genetic alterations.

AML Treatment Additions Encouraging, But MDS Landscape Still Facing Challenges

March 31st 2018

Stuart L. Goldberg, MD, discusses the management of patients with acute myeloid leukemia as well as those with myelodysplastic syndrome.

The Evolving Treatment Landscape of CLL

March 31st 2018

Relapsed/Refractory CLL: Evaluating Other Novel Agents

March 31st 2018

Novel Approaches to Treating Relapsed/Refractory CLL

March 31st 2018

Continuing Therapy in Relapsed/Refractory CLL

March 31st 2018

Evaluating Pharmacologic Agents in Relapsed/Refractory CLL

March 31st 2018

CLL: Post-Ibrutinib or Chemoimmunotherapy Approaches

March 31st 2018

Approaching Therapy for Relapsed/Refractory CLL

March 31st 2018

Novel Frontline Combinations With Ibrutinib in CLL

March 31st 2018

Ibrutinib's Value as Frontline Therapy in CLL

March 31st 2018

Sequencing Strategies in Frontline CLL

March 31st 2018